National Institute on Drug Abuse; Notice of Closed Meeting, 36612 [2019-16021]

Download as PDF 36612 Federal Register / Vol. 84, No. 145 / Monday, July 29, 2019 / Notices 2019. The closed session is amended to end at 9:30 a.m. and the open session is amended to begin at 9:30 a.m. The meeting is partially closed to the public. DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting National Institute on Alcohol Abuse and Alcoholism; Amended Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The cooperative agreement applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the cooperative agreement applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Notice is hereby given of a change in the meeting of the Board of Scientific Counselors, NIAAA, September 18, 2019, 8:30 a.m. to September 18, 2019, 3:30 p.m., National Institutes of Health, Building 10, Conference Room I–2330, 10 Center Drive, Bethesda, MD 20892 which was published in the Federal Register on February 26, 2019, 84 FR 6155. This meeting notice is amended to change the meeting location from Building 10, Conference Room I–2330, 10 Center Drive, Bethesda, MD 20892 to 5625 Fishers Lane, 5th Floor Conference Room, Rockville, MD 20852. The meeting is closed to the public. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3—Clinical Trials Optional). Date: August 22, 2019. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate cooperative agreement applications. Place: Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852. Contact Person: Ivan K. Navarro, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, Division of Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892, 301–827–5833, ivan.navarro@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: July 24, 2019. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–16021 Filed 7–26–19; 8:45 am] BILLING CODE 4140–01–P Dated: July 24, 2019. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–16020 Filed 7–26–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Submission for OMB Review; 30-Day Comment Request National Cancer Institute (NCI) a Generic Submission for Formative Research, Pretesting and Customer Satisfaction of NCI’s Communication and Education Resources (NCI); Correction AGENCY: Dated: July 24, 2019. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. National Institutes of Health, HHS. ACTION: Notice; correction. The Department of Health and Human Services, National Institutes of Health published a Notice in the Federal Register on July 2, 2019. That Notice requires a correction in the SUPPLEMENTARY INFORMATION section. FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Ilene French, Branch Chief, Office of Communication and Public Liaison, National Cancer Institute, 9609 Medical Center Drive, Maryland, 20892 or call non-toll-free number (240) 276–7787 or Email your request, including your address to: nciocpl@mail.nih.gov. SUPPLEMENTARY INFORMATION: SUMMARY: [FR Doc. 2019–16013 Filed 7–26–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Alcohol Abuse and Alcoholism; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Advisory Council on Alcohol Abuse and Alcoholism, September 19, 2019, 9:00 a.m. to September 19, 2019, 3:00 p.m., National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Bethesda, MD 20817 which was published in the Federal Register on February 05, 2019, 84 FR 1757. This meeting notice is amended to change the meeting date from September 19, 2019 to September 12, Correction In the Federal Register of July 2, 2019, in FR Doc. 2019–14071, on page 31605, correct the Estimated Annualized Burden Hours table to read as follows: khammond on DSKBBV9HB2PROD with NOTICES ESTIMATED ANNUALIZED BURDEN HOURS Form name Type of respondents Focus Groups, Individual In-Depth Interviews, Brief Interviews, Surveys, Website Usability Testing. Individuals ..... (General Public). VerDate Sep<11>2014 16:54 Jul 26, 2019 Jkt 247001 PO 00000 Frm 00048 Fmt 4703 Number of respondents Sfmt 4703 Number of responses per respondent 9,000 E:\FR\FM\29JYN1.SGM 1 29JYN1 Average time per response (in hours) 45/60 Total annual burden hours 6,750

Agencies

[Federal Register Volume 84, Number 145 (Monday, July 29, 2019)]
[Notices]
[Page 36612]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-16021]



[[Page 36612]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The cooperative agreement applications and the 
discussions could disclose confidential trade secrets or commercial 
property such as patentable material, and personal information 
concerning individuals associated with the cooperative agreement 
applications, the disclosure of which would constitute a clearly 
unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Development of Medications to Prevent and Treat 
Opioid Use Disorders and Overdose (UG3/UH3--Clinical Trials 
Optional).
    Date: August 22, 2019.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: Hilton Washington/Rockville, 1750 Rockville Pike, 
Rockville, MD 20852.
    Contact Person: Ivan K. Navarro, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892, 
301-827-5833, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: July 24, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-16021 Filed 7-26-19; 8:45 am]
 BILLING CODE 4140-01-P


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.